# Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

> **NCT06141473** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 1655 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Frexalimab
- **DRUG:** Teriflunomide
- **DRUG:** Placebo infusion
- **DRUG:** Placebo tablet
- **DRUG:** MRI contrast-enhancing agents
- **DRUG:** Cholestyramine
- **DRUG:** Activated charcoal

## Key facts

- **NCT ID:** NCT06141473
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-13
- **Primary completion:** 2027-05-06
- **Final completion:** 2027-05-06
- **Target enrollment:** 1655 (ACTUAL)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06141473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06141473, "Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06141473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*